Walleye Trading’s Akebia Therapeutics AKBA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-44,901
Closed -$129K 5290
2021
Q3
$129K Sell
44,901
-44,892
-50% -$128K ﹤0.01% 4216
2021
Q2
$340K Buy
89,793
+71,952
+403% +$242K ﹤0.01% 3360
2021
Q1
$60K Sell
17,841
-18,471
-51% -$66.5K ﹤0.01% 4280
2020
Q4
$102K Buy
+36,312
New +$106K ﹤0.01% 3925
2019
Q3
Sell
-5,910
Closed -$29K 3967
2019
Q2
$29K Buy
+5,910
New +$33.6K ﹤0.01% 3672
2018
Q2
Sell
-14,500
Closed -$138K 4518
2018
Q1
$138K Buy
+14,500
New +$203K ﹤0.01% 3740
2015
Q4
Sell
-980
Closed -$9K 5225
2015
Q3
$9K Buy
+980
New +$8.99K ﹤0.01% 4406

Other funds holding AKBA

Walleye Trading's AKBA Position: Q4 2021 in Review

Walleye Trading sold out of Akebia Therapeutics (AKBA) in Q4 2021, closing a stake of 44,901 shares — an estimated $129K sold.

Walleye Trading first reported a position in AKBA in Q3 2015 and held it in 7 quarters. The position peaked at $340K in Q2 2021. 133 funds tracked by Wall St. Rank hold AKBA as of Q4 2021.

  • Walleye Trading reported no remaining Akebia Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Walleye Trading sold 44,901 Akebia Therapeutics shares in Q4 2021, an estimated $129K.
  • Walleye Trading first reported a position in Akebia Therapeutics in Q3 2015 and held it in 7 quarters.
  • Walleye Trading's Akebia Therapeutics position peaked at $340K in Q2 2021.
  • 133 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2021.

Based on Walleye Trading's 13F filing for Q4 2021, filed 14 Feb 2022.